Regulatory Authorities and Requests for Unblinded DMC Data and Reports
This article was originally published in SRA
Executive Summary
There has been an increase in requests from regulatory authorities for unblinded DMC data and reports. Mats Ericson, Shamim Ruff, Alan Morrison, James Matcham and Steve Snapinn examine the issues and argue that such requests should as a matter of principle be challenged and preferably denied.
You may also be interested in...
Hanmi And LG Chem Highlight Vaccine Prowess, Novel R&D At JPM
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vaccination Health Next Stop For Dentovations’ Self+ Immunity Supplement Line
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: